Skip to content

Study · Observational study · n = 40 · 2024

8 results

Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study.

Sawamura T, Mizoguchi R, Ohmori A, Kometani M, Yoneda T, Karashima S

Journal of diabetes and metabolic disorders26 Jul 2024Cited by 10 (Europe PMC)

PMID39610482 (opens in a new tab)PMCIDPMC11599550 (opens in a new tab)DOI10.1007/s40200-024-01472-w (opens in a new tab)PepBankPUB-39610482
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

ObjectivesTirzepatide belongs to a new class of anti-diabetic agents that stimulate both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, resulting in a greater blood glucose-lowering effect and body weight reduction than glucagon-like peptide-1 analogs. However, data on the effects of switching from glucagon-like peptide-1 analogs to tirzepatide on the blood glucose level, body weight, and liver functions are unavailable.MethodsData from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch. The analyzed data included glycosylated hemoglobin, body weight, aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase levels, and fibrosis-4 index.ResultsSix months after the treatment switch, average reductions of 1.2% and 3.6 kg were observed in the glycosylated hemoglobin and body weight, respectively. The change in glycosylated hemoglobin level was negatively correlated with the baseline glycosylated hemoglobin level. However, body weight reduction was observed regardless of the baseline characteristics. Moreover, the aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels decreased 6 months after the switch. Reductions in alanine aminotransferase levels was greater in patients with higher baseline aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels. Although the fibrosis-4 index did not improve during the study period, a trend toward a decrease was observed in patients with a higher baseline fibrosis-4 index.ConclusionsSwitching from dulaglutide to tirzepatide has a beneficial effect on the blood glucose level, body weight, and liver function in patients with type 2 diabetes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In diabetes patients, switching from dulaglutide to tirzepatide was linked to an average HbA1c reduction of 1.2% after six months.

    In plain wordsIn diabetes patients, switching from dulaglutide to tirzepatide was linked to lower HbA1c than baseline.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c after switch
    Study

    n = 40

    Comparator
    Baseline before switch from dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    HbA1c reduction
    1.2%
    6 months after switch from dulaglutide to tirzepatide

    Source sentences

    Summary
    Six months after the treatment switch, average reductions of 1.2% and 3.6 kg were observed in the glycosylated hemoglobin and body weight, respectively.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.
  2. 02HumanObservational studyEfficacy outcome

    In diabetes patients, switching from dulaglutide to tirzepatide was linked to an average weight reduction of 3.6 kg after six months.

    In plain wordsIn diabetes patients, switching from dulaglutide to tirzepatide was linked to lower weight than baseline.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight after switch
    Study

    n = 40

    Comparator
    Baseline before switch from dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Body weight reduction
    3.6 kg
    6 months after switch from dulaglutide to tirzepatide

    Source sentences

    Summary
    Six months after the treatment switch, average reductions of 1.2% and 3.6 kg were observed in the glycosylated hemoglobin and body weight, respectively.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.
  3. 03HumanObservational studyEfficacy outcome

    After switching from dulaglutide to tirzepatide, HbA1c change was negatively correlated with baseline HbA1c.

    In plain wordsIn diabetes patients switching from dulaglutide to tirzepatide, higher baseline HbA1c was linked to a more negative HbA1c change.

    Peptide
    Tirzepatide
    Outcome
    Not applicableBaseline HbA1c association with HbA1c change
    Study

    n = 40

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The change in glycosylated hemoglobin level was negatively correlated with the baseline glycosylated hemoglobin level.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.
  4. 04HumanObservational studyEfficacy outcome

    In diabetes patients, aspartate aminotransferase decreased six months after switching from dulaglutide to tirzepatide.

    In plain wordsIn diabetes patients, a liver enzyme decreased from baseline after switching from dulaglutide to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAspartate aminotransferase
    Study

    n = 40

    Comparator
    Baseline before switch from dulaglutide
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Moreover, the aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels decreased 6 months after the switch.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.
  5. 05HumanObservational studyEfficacy outcome

    In diabetes patients, alanine aminotransferase decreased six months after switching from dulaglutide to tirzepatide.

    In plain wordsIn diabetes patients, alanine aminotransferase decreased from baseline after switching from dulaglutide to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAlanine aminotransferase
    Study

    n = 40

    Comparator
    Baseline before switch from dulaglutide
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Moreover, the aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels decreased 6 months after the switch.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.
  6. 06HumanObservational studyEfficacy outcome

    In diabetes patients, gamma-glutamyl transpeptidase decreased six months after switching from dulaglutide to tirzepatide.

    In plain wordsIn diabetes patients, gamma-glutamyl transpeptidase decreased from baseline after switching from dulaglutide to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseGamma-glutamyl transpeptidase
    Study

    n = 40

    Comparator
    Baseline before switch from dulaglutide
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Moreover, the aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels decreased 6 months after the switch.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.
  7. 07HumanObservational studyEfficacy outcome

    After switching to tirzepatide, ALT reductions were greater in patients with higher baseline AST, ALT, and gamma-glutamyl transpeptidase.

    In plain wordsAfter switching from dulaglutide to tirzepatide, patients with higher baseline liver enzymes had larger ALT reductions than those with lower levels.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBaseline liver enzyme association with ALT reduction
    Study

    n = 40

    Comparator
    Patients with lower baseline liver enzymes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Reductions in alanine aminotransferase levels was greater in patients with higher baseline aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.
  8. 08HumanObservational studyEfficacy outcome

    In diabetes patients, the fibrosis-4 index did not improve during the study after switching from dulaglutide to tirzepatide.

    In plain wordsIn diabetes patients, the fibrosis index did not improve from baseline after switching from dulaglutide to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeFibrosis-4 index overall
    Study

    n = 40

    Comparator
    Baseline before switch from dulaglutide
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Although the fibrosis-4 index did not improve during the study period, a trend toward a decrease was observed in patients with a higher baseline fibrosis-4 index.
    1 context sentence
    Summary · context
    Data from 40 patients with type 2 diabetes who received a prescription change from dulaglutide to tirzepatide were retrospectively analyzed at the 3 and 6 months after the switch.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.